Nina Kjellson has been part of InterWest's life sciences team since 2002, focusing primarily on investments in biopharmaceuticals.
She is a board member of Alvine Pharmaceuticals, Cebix, Eiger Biopharmaceuticals, Labrys, Lycera, PrimeraDx, Trius Therapeutics (TSRX), Welltok and Xenon. Nina co-sponsored InterWest's investments in TESARO and Sera Prognostics where she is also a board observer. She also leads InterWest's initiative in health care IT and is a director of the Consumer Medicine Summit, a forum to address the convergence of health care and consumer innovation, and serves as a mentor to the Nike+ Accelerator and to Blueprint Health.

Prior to joining InterWest, Nina was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a health care-focused hedge fund. Nina began her career conducting health policy and survey research with the Kaiser Family Foundation.

Nina received a B.A. in human biology from Stanford University.

Prior Investments

Aspreva Pharmaceuticals (IPO 2006, ASPV), NovaCardia (Acquired by Merck in 2007), CNS Therapeutics (Acquired by Covidien in 2012)